-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8

Benzinga·03/30/2026 17:55:13
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $12 to $8.